Welcome to our dedicated page for BiomX SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BiomX Inc. (PHGE) SEC filings document a public company whose reported focus has shifted from legacy phage therapy development toward defense, security, and critical infrastructure technology. Recent filings include quarterly reports, amended annual report material, current reports on Form 8-K, shareholder voting disclosures, material agreements, capital-structure items, governance matters, and risk-factor disclosures.
PHGE’s 10-Q filings are important because BiomX reports as a single operating segment and presents its financial information on a consolidated basis. The quarterly filing also states that the company has incurred significant losses and negative cash flows from operations and that these factors raise substantial doubt about its ability to continue as a going concern.
BiomX 8-K filings are especially relevant because recent material-event reports describe the Zorronet acquisition, shareholder approvals, and a framework supply agreement involving Israel Railways. These filings provide details on Zorronet’s AI-powered computer vision, autonomous surveillance, threat detection, object recognition, perimeter intrusion identification, and command-and-control integrations.
Annual reports on 10-K and amended annual reports on 10-K/A provide governance, compensation, equity plan, and business-history context. Proxy materials show shareholder voting matters. Form 4 insider transaction filings, when filed, identify changes in beneficial ownership by company insiders. For PHGE, the most relevant filing themes are Zorronet and DFSL operating disclosures, legacy phage therapy background, going-concern language, governance changes, and material agreements tied to defense and infrastructure markets.
BiomX Inc. (PHGE) is implementing a capital and branding change that includes a reverse stock split and a corporate name change. A Certificate of Amendment effective at 12:01 a.m. Eastern Time on September 9, 2026 effects a one-for-ten reverse stock split of the company’s common stock and reduces authorized common shares from 750,000,000 to 150,000,000. Trading in the common stock on the NYSE American will begin on a split-adjusted basis on September 9, 2026 under CUSIP 09090D 608, with fractional shares rounded up to the nearest whole share at the record holder and DTC participant level. A separate amendment will become effective at 12:01 a.m. Eastern Time on September 11, 2026, changing the company’s name from BiomX Inc. to Tessera Defense and Homeland Security Inc., after which the stock will trade under the new ticker symbol HLSQ on the NYSE American while retaining the same CUSIP number.
BiomX Inc. (PHGE) reported that it will change its corporate name to Tessera Defense and Homeland Security Inc., effective at 12:01 a.m. ET on September 11, 2026, following approval by its Board of Directors. Under Delaware law, no stockholder approval is required, and the company plans to file a certificate of amendment to its charter to implement the change.
On September 11, 2026, the common stock will begin trading on the NYSE American under the new ticker symbol HLSQ, and will trade under PHGE until then. The shares will be identified by CUSIP 09090D 608, which is being assigned in connection with a previously announced one-for-ten reverse stock split expected to become effective on September 9, 2026 and will not change as a result of the name change. The company states that the name change and reverse stock split are separate corporate actions, do not affect stockholder rights, and require no action or certificate exchange by stockholders.
BiomX Inc. (PHGE) is implementing a one-for-ten reverse stock split of its common stock. The Board fixed the split ratio at 1-for-10 and expects it to become effective at 12:01 a.m. Eastern Time on September 9, 2026, after filing a Certificate of Amendment in Delaware that also reduces authorized common shares from 750,000,000 to 150,000,000.
Each block of ten pre-split shares will be combined into one post-split share, reducing outstanding common stock from approximately 27.3 million shares as of August 31, 2026 to approximately 2.7 million, without changing par value. Holders of record who would otherwise receive fractional shares will receive one whole share instead, while fractional interests for beneficial owners in street name will be handled under nominee procedures. Proportionate adjustments will apply to outstanding warrants, convertible instruments and equity awards, and the reverse split is expected to affect all stockholders uniformly aside from minor changes from fractional share treatment.
BiomX Inc. (PHGE) announced a 1-for-10 reverse stock split of its common stock. The Board set the ratio on August 28, 2026, after prior stockholder approval of a reverse split in the range of 1-for-5 to 1-for-20, together with a reduction in authorized shares.
The reverse split and related Certificate of Amendment are expected to become effective at 12:01 a.m. ET on September 9, 2026, with trading on the NYSE American beginning on a split-adjusted basis that day. Each 10 pre-split shares will be combined into 1 post-split share, reducing outstanding shares from approximately 26.7 million to approximately 2.7 million, while authorized common shares will decrease from 750,000,000 to 150,000,000. Fractional shares will be rounded up to the next whole share, and percentage ownership will remain essentially unchanged aside from rounding effects.
BiomX Inc. (PHGE) reported results of a Special Meeting of Stockholders held on August 25, 2026. As of the August 10, 2026 record date, 26,559,607 shares of common stock were outstanding and entitled to vote, with 9,813,430 shares present, representing 36.9% of eligible shares and constituting a quorum.
Stockholders approved the issuance of common stock and related securities to Mandragola Ltd. in connection with acquiring controlling equity interests in Dr. Frucht Systems Ltd., including securities linked to a Line of Credit and a potential Revenue Bonus. They also approved a reverse stock split authorization at a ratio between 1-for-5 and 1-for-20, to be implemented at the Board’s discretion before the first anniversary of the Special Meeting; if implemented, authorized common shares would decrease from 750,000,000 to 150,000,000. Stockholders ratified Barzily & Co. as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved an adjournment proposal, though no adjournment was needed.
BiomX Inc. (PHGE) is the subject of this Amendment No. 5 to a Schedule 13G/A filed by the Cystic Fibrosis Foundation. The foundation reports beneficial ownership of 174,276 shares of BiomX common stock, representing 1.47% of the class, with sole voting and dispositive power over all reported shares. The filing indicates that the Cystic Fibrosis Foundation now owns 5 percent or less of BiomX’s common stock.
BiomX Inc. (PHGE) reports a major strategic and financial transformation for the quarter ended June 30, 2026, shifting from phage-based drug development to defense, security and critical infrastructure technology. It completed business acquisitions of ZorroNet and a 60% stake in DFSL, adding $25.4 million of goodwill and other intangibles and creating $6.8 million of non‑controlling interests. Total assets rose to $28.2 million from $5.8 million at December 31, 2025, and stockholders’ equity moved from a deficit of $(1.3) million to positive equity of $17.6 million, driven largely by these transactions and warrant-related equity issuances.
Operations remain highly loss‑making and cash‑constrained. Revenue for the first half of 2026 was $0.3 million, while net loss was $23.0 million, including large non‑cash charges from warrant and derivative remeasurement and a $5.2 million day‑one loss on a financing transaction, partly offset by a $1.9 million gain from deconsolidating insolvent BiomX Israel. Operating cash outflow was $6.6 million and period‑end cash and cash equivalents were only $0.3 million. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern absent additional financing, and plans to rely on equity/debt raises, an at‑the‑market program, and new revenue from DFSL and ZorroNet.
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of BiomX Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 730,551 shares, including 95,556 shares that may be acquired within sixty days through exercise of convertible securities.
This position represents 7.13% of BiomX’s outstanding common stock for each reporting person. All 730,551 shares are reported with shared voting and shared dispositive power; none of the reporting persons has sole voting or dispositive power over these shares.
BiomX Inc. shareholder group led by Telmina Limited and related entities filed an amendment updating beneficial ownership of the company’s common stock. The group, including Telmina Limited, Centaurus Investments Limited, Geneva Holding Company (GHC) SA, Geneva Trust Company (GTC) SA, and individual Rodney Hodges, reports beneficial ownership of 82,618 shares of common stock.
The holdings represent 0.7% of BiomX’s common stock, based on 11,797,449 shares outstanding as of June 22, 2026, as referenced in a prospectus. The reported position includes 33,934 warrants held by Telmina Limited that are exercisable within 60 days of August 13, 2026. Voting and dispositive power over all 82,618 shares is reported as shared among the reporting persons, with no sole voting or dispositive power.